GlobeNewswire Inc.··Hagens BermanCorcept Faces Securities Lawsuit Over Relacorilant FDA Rejection
Corcept Therapeutics faces securities lawsuit alleging it misrepresented relacorilant's FDA approval prospects, causing stock to plunge 50% after regulatory rejection.
CORTsecurities fraudclass action lawsuit